Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Compounded analgesic preparation containing cobratide and oxycodone

A technology of oxycodone and cobotide, which is applied in the field of medicine, can solve the problems of poor stability, easy to cause allergic reactions, and slow onset of action, and achieve the effects of reduced toxic and side effects, strong analgesic effect, and fast peak time Effect

Active Publication Date: 2015-05-27
GUIZHOU YIBAI PHARMA CO LTD
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, because kebotide is a heterologous protein for the human body, it is immunogenic and can easily cause allergic reactions; its onset is slow and its stability is poor, so its clinical application has certain limitations
[0005] At present, there are many drugs for treating pain, but due to problems such as adverse reactions and addiction, there are many defects and deficiencies in clinical application, which cannot meet the clinical needs well; For the clinical pharmacological performance of codone, it will be of great significance to use a large number of experiments to screen prescriptions and explore a drug preparation with fast onset, strong and long-lasting analgesic effect, and avoid or reduce addiction, dependence and other adverse reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounded analgesic preparation containing cobratide and oxycodone

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment 1: small volume injection: A1

[0023] Take 800ml of water for injection, add potassium hydroxide to adjust the pH value to 5, add 9g of sodium chloride and stir, heat to 35°C, add 0.016g of cobotide, 1.6g of oxycodone, and then add 0.2g of Tween-80 To aid dissolution, stir until the solution is clear, add water for injection with adjusted pH value to 1000ml, filter and sterilize, and pack into ampoules to obtain 400 small-volume injections. The specification is 2.5ml each, containing 40μg of effective dose of Cobotide and 4mg of Oxycodone.

Embodiment 2

[0024] Embodiment 2: small volume injection: A2

[0025] Take 800ml of water for injection, add sodium hydroxide to adjust the pH value to 6, add 8g of sodium chloride and stir, heat to 37°C, add 0.024g of cobotide, 3.2g of oxycodone hydrochloride, and then add 0.16g of Tween- 80 to aid dissolution, stir until the solution is clear, then make up water for injection with adjusted pH value to 1000ml, filter and sterilize, and pack into ampoules to obtain 400 small-volume injections. The specification is 2.5ml each, containing 60μg of effective dose of cobotide and 8mg of oxycodone.

Embodiment 3

[0026] Embodiment 3: small volume injection: A3

[0027] Take 700ml water for injection, add sodium carbonate to adjust the pH value to 7, add 10g sodium chloride and stir, heat to 36°C, add 0.032g cobotide, 4.8g oxycodone hydrochloride active ingredient, and then add 0.24g porol Sham 188, stirred until the solution is clear, then supplemented with water for injection with adjusted pH value to 1000ml, filtered and sterilized, and divided into ampoules to obtain 400 small-volume injections. The specification is 2.5ml each, containing 80μg of effective dose of Cobotide and 12mg of Oxycodone.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a compounded analgesic preparation containing cobratide and oxycodone, which includes following raw materials, by weight, 0.04-0.08 parts of the cobratide and 4-12 parts of an oxycodone active component. The oxycodone active component is the oxycodone and a pharmaceutically-acceptable salt thereof. An experimental result proves that the compounded analgesic preparation can alleviate terminal cancer pain, chronic joint pain, sciatica, neuropathic headache, prosopalgia and lepra reaction neuralgia and the like chronic pains, is especially suitable for chronic, refractory and durable pains, is quick in effect, is strong and durable in analgesic effect, can avoid or reduce addiction and dependency and is high in stability. The compounded analgesic preparation containing the cobratide and the oxycodone can be used as an ideal medicine for cancer-used analgesia.

Description

Technical field: [0001] The invention belongs to the technical field of medicine and relates to a pharmaceutical preparation for preventing and treating pain, in particular to a compound analgesic injection containing cobotide and oxycodone. Background technique: [0002] Pain is an unpleasant feeling and emotional experience that occurs when the body is damaged. It is a clinical manifestation of a group of complex pathological and physiological changes. Pain can be local or a reflection of systemic diseases. The above diseases with "pain" as the main symptom are collectively referred to as "pain". At present, opioid analgesics and non-steroidal anti-inflammatory drugs are classic clinical analgesics, and have a long history of being used in pain treatment. However, there are also many defects and deficiencies in its clinical application, and the adverse reactions are also daunting. For example, some strong opioid analgesics that are clinically used for severe pain after s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K9/08A61K9/19A61P29/00A61P25/02A61P25/04A61K31/485
Inventor 窦啟玲
Owner GUIZHOU YIBAI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com